Publication of the first transnational call of the ERDERA (European Rare Diseases Research Alliance) partnership: 'Pre-clinical therapy studies for rare diseases using small molecules and biologicals - development and validation'
On 11 December 2024, the Ministry of Health (hereinafter referred to as the "Ministry of Health") publishes, in accordance with Act No. 130/2002 Coll., on support for research, experimental development and innovation from public funds and on amendments to certain related acts (Act on support for research, experimental development and innovation), as amended (hereinafter referred to as the "Act"),
the first transnational call of the ERDERA (European Rare Diseases Research Alliance) partnership: 'Pre-clinical therapy studies for rare diseases using small molecules and biologicals - development and validation'
Call 2025
Basic information
Deadline for announcement of results
December 2025
National budget allocation for the call
500 000 EUR
Maximum amount of support per project
250 000 EUR
Maximum aid intensity per project
Table 8: Maximum possible aid intensity by type of entity and type of research (Methodology: European Health Partnerships, p. 66)
Applicants
research organisation, enterprise
Project duration
3years / 36 months
Deadlines for submission of project proposals:
Pre-proposals: 13 February 2025, 14:00 CET
Full proposals: 9 July 2025, 14:00 CEST
Interested parties are invited to attend the International Information Webinar on December 17, 2024 from 14:00 - 16:00 (CET). Registration is mandatory. The form to complete is available at this link: REGISTRATION
DOCUMENTS
Documents for Czech applicants
Conditions for the Czech bidder's participation in ERDERA Call 2025
Methodology: European Partnerships for Health
Sub-programme 3: European Partnerships in Health - effective from 22.5.2024
Mandatory annexes of the Czech applicant for Phase 2 (full proposals)
Documents on professional competence according to the nature of the project;
Updated budget table (AZV ČR Application Form)
Other documents
Definition of types of results
ERDERA Call 2025 Support Contract
The official call documents are available here
Information about the call
The first transnational call of the ERDERA (European Rare Diseases Research Alliance) partnership "Pre-clinical therapy studies for rare diseases using small molecules and biologicals - development and validation" aims to:
- Development of new therapies in the preclinical setting through studies in cellular, organoid and animal models, and/or the use of in silico models or artificial intelligence to accelerate the success of the preclinical phase.
- Development of predictive and pharmacodynamic biomarkers related to therapy efficacy in the preclinical setting that could serve as surrogate target markers.
- Repeat preclinical studies in an independent laboratory to verify and confirm the accuracy of the original results.
- Pre-clinical 'proof of concept' studies to provide evidence of in vitro and in vivo pharmacological activity, pharmacokinetics and pharmacodynamics of the investigational medicinal product (e.g. small molecules and/or biologics) and initial toxicity and safety data, as well as studies supporting readiness to initiate clinical trials in accordance with regulatory requirements.
Project proposals must cover at least two of the above areas.
Size of the project consortium
The consortium must include 4 to 6 eligible partners from at least 4 different countries participating in this call. One of these 4 to 6 partners must be anEarly Career Researcher (ERC). In specific cases, the number of partners may be increased to 8. A maximum of 2 eligible partners from the same country are allowed per consortium. Patient organisations applying for funding are not included in the total number. The consortium may also include collaborators, provided that it secures its own funding.
List of participating countries:
Austria (FWF), Belgium (FNRS, FWO, SPW), Bulgaria (BNSF), Canada (CIHR-IG), Czech Republic (MZCR/AZVCR), Cyprus (RIF), Italy (MoH-IT, MUR, FTELE), Italy (Lombardy - FRRB), Italy (Tuscany - RT/TuscReg), Latvia (LZP), Lithuania (LMT), Luxembourg (FNR), Norway (RCN), Poland (NCBR), Denmark (IFD), Estonia (ETAG), France (ANR, FFRD), Germany (BMBF, DFG), Hungary (NKFIH), Iceland (RANNIS), Ireland (HRB), Israel (CSO-MOH), Portugal (FCT), Slovakia (SAS), Spain (ISCIII), Sweden (Vinnova), Switzerland (SNSF), Netherlands (ZonMw), Turkey (TUBITAK).
*The list of participating countries is current as of 10 December 2024.
Call rules:
The call is governed by transnational rules common to applicants from all participating countries. In addition to the transnational rules, Czech applicants must also comply with the national conditions set by the relevant national provider. Applicants participating in applied research projects will therefore have to comply with national conditions based on Sub-programme 3: European Partnerships in Health.
Contact person:
Mgr. Monika Kocmanová
+ 420 778 973 186
You can also submit questions about the transnational call via email: .